STAB1 and hepatocellular carcinoma: A recent Phase I/II first-in-man clinical trial in advanced solid tumour cancer patients, including HCC, targeted stabilin-1 with a humanised function blocking antibody (bexmarilimab) and demonstrated a significant switch in phenotypes of circulating monocytes and intratumoural macrophages in treatment responders, when compared with non-responders [201].